Molecular and Functional PET-fMRI Measures of Analgesia in Migraine
|ClinicalTrials.gov Identifier: NCT01970943|
Recruitment Status : Unknown
Verified January 2015 by David Borsook, Mclean Hospital.
Recruitment status was: Active, not recruiting
First Posted : October 28, 2013
Last Update Posted : January 30, 2015
|Condition or disease||Intervention/treatment||Phase|
|Migraine Healthy||Other: Placebo||Phase 2|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||28 participants|
|Intervention Model:||Crossover Assignment|
|Primary Purpose:||Basic Science|
|Official Title:||Molecular and Functional PET-fMRI Measures of Analgesia in Migraine|
|Study Start Date :||March 2013|
|Primary Completion Date :||April 2014|
No Intervention: No Intervention
PET-fMRI investigation on healthy subjects and patients with migraine. No drug condition.
Placebo Comparator: Saline Injection (Placebo)
PET-fMRI investigation on healthy subjects and patients with migraine. Placebo condition.
Placebo will be compared to No Intervention.
- VAS Pain rating [ Time Frame: 1 day ]This study will investigate how placebo may reduce experimental pain induced by contact heat.
- fMRI BOLD signal [ Time Frame: 1 day ]Functional Magnetic Resonance Imaging Blood Oxygenation Level Dependent Signal will be obtained.
- PET Diprenorphine [ Time Frame: 1 day ]Positron Emission Tomography with C11 diprenorphine will be used to measure opioid receptors
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01970943
|United States, Massachusetts|
|Athinoula A. Martinos. Center for Biomedical Imaging|
|Charlestown, Massachusetts, United States, 02129|
|Principal Investigator:||David Borsook, MD, Ph.D||Boston Children’s Hospital|